CMPS — COMPASS Pathways Share News
0.000.00%
Last trade - 00:00Trump's psychedelic drug order boosts investor interest with promise of faster reviews
UK's Compass Pathways Q1 operating income beats estimates as expenses fall
Health Rounds: Researchers gain new insight into how psychedelics affect the brain
U.S. STOCKS ON THE MOVE-Eli Lilly, Compass Pathways, Charter Communications
Brief: Compass Pathways Says FDA Granted NDA Rolling Review Request & Awarded Commissioner's National Priority Voucher
U.S. STOCKS ON THE MOVE-Zoom, Compass Pathways, X-Energy
Compass Pathways rises after FDA fast-tracks psychedelic drug research
US FDA moves to fast-track psychedelic drugs after Trump order (updated)
Explainer: What to know about psychedelic therapies cited by Trump
U.S. STOCKS ON THE MOVE-Adobe, Biogen, Sable
Psychedelic drug developers rise after Trump signals regulatory support
U.S. STOCKS ON THE MOVE-Adobe, Agios, QXO
U.S. STOCKS ON THE MOVE-TopBuild, MDA Space, Biogen
Psychedelic drug developers rally as Trump orders FDA to expedite reviews (updated)
Psychedelic drug makers rally as Trump orders FDA to expedite reviews
Psychedelic drug developers rise after Trump signals regulatory support
Brief: Compass Pathways Commends White House Executive Order To Accelerate Research And Access For Psychedelic Treatments
Psychedelic drug developers rise after CBS report Trump backs more research
U.S. STOCKS ON THE MOVE-BlackRock, MDA Space, Revolution Medicines